A Phase 2/3 interventional study of AC-170 0.05% and AC-170 0.1% in Allergic Conjunctivitis, sponsored by Aciex Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2017-08-30.
Sponsored by Aciex Therapeutics, Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Conjunctivitis, Allergic with a site in United States — 6 open to participants now, 7 under way, 2 of them phase 3. Conjunctivitis, Allergic · United States.
Among the 95 studies in Conjunctivitis, Allergic with a site in United States, this one is the 39th largest by enrollment of the 90 interventional ones that give a count, is one of 10 that started in 2011, is one of 2 in phase 2/3, and was the 39th registered.
211 studies on the registry are indexed under Conjunctivitis, Allergic; 19 are open to participants now.
Browse Conjunctivitis, Allergic studies →6 of the 95 studies in Conjunctivitis, Allergic with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 8+
Dompé Farmaceutici S.p.A · Sites in United States, Argentina, Czechia and 11 more countries
Ages 18+
Telios Pharma, Inc. · Sites in United States
Ages 18+
Telios Pharma, Inc. · Sites in United States
Ages 18+
Telios Pharma, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Conjunctivitis, Allergic studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 10 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 29 · Phase 3 36 · Phase 4 20
First in 2000; this study’s year is marked. 10 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 101 is above the median of 87 across 175 interventional studies indexed under Conjunctivitis, Allergic.
Median enrollment 94 across the 90 interventional studies, 100 across the 5 observational. Of the 84 that completed or were terminated, 50 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
81 of 95 have an industry lead sponsor. The 10 most frequent:
Aciex Therapeutics, Inc. is the lead sponsor of 8 studies on the registry; none are open to participants now.
Aciex Therapeutics, Inc. has 6 studies filed under Conjunctivitis, Allergic — fewer than ten, so there is no comparison to draw.
1 of the studies in Conjunctivitis, Allergic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07938632Telios Pharma, Inc.TL-925 for the Treatment of Allergic Conjunctivitis | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 95 studies in Conjunctivitis, Allergic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of different concentrations of AC-170 compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) Model.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AC-170 0.05%
Drug: AC-170 0.1%
Drug: AC-170 0.24%
Drug: AC-170 0%
1 drop in each eye at 3 separate times during a 21 day period
1 drop in each eye at 3 separate times during a 21 day period
1 drop in each eye at 3 separate times during a 21 day period
1 drop in each eye at 3 separate times during a 21 day period
Ocular Itching at Duration of Action (16 Hours Post-dose)
A treatment efficacy CAC was performed 16 hours after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.
Time frame: 3, 5, 7 minutes post-CAC
Ocular Itching at Duration of Action (24 Hours Post-dose)
A treatment efficacy CAC was performed 24 hours after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.
Time frame: 3, 5, 7 minutes post-CAC
Ocular Itching at Onset of Action (15 Minutes Post-dose)
A treatment efficacy CAC was performed 15 minutes after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.
Time frame: 3, 5, 7 minutes post-CAC
Conjunctival Redness at Duration of Action (16 Hours Post-dose)
A treatment efficacy CAC was performed 16 hours after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Conjunctival Redness at Duration of Action (24 Hours Post-dose)
A treatment efficacy CAC was performed 24 hours after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Conjunctival Redness at Onset of Action (15 Minutes Post-dose)
A treatment efficacy CAC was performed 15 minutes after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Ciliary Redness at Duration of Action (16 Hours Post-dose)
A treatment efficacy CAC was performed 16 hours after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Ciliary Redness at Duration of Action (24 Hours Post-dose)
A treatment efficacy CAC was performed 24 hours after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Ciliary Redness at Onset of Action (15 Minutes Post-dose)
A treatment efficacy CAC was performed 15 minutes after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Episcleral Redness at Duration of Action (16 Hours Post-dose)
A treatment efficacy CAC was performed 16 hours after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Episcleral Redness at Duration of Action (24 Hours Post-dose)
A treatment efficacy CAC was performed 24 hours after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Episcleral Redness at Onset of Action (15 Minutes Post-dose)
A treatment efficacy CAC was performed 15 minutes after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Chemosis at Duration of Action (16 Hours Post-dose)
A treatment efficacy CAC was performed 16 hours after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Chemosis at Duration of Action (24 Hours Post-dose)
A treatment efficacy CAC was performed 24 hours after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Chemosis at Onset of Action (15 Minutes Post-dose)
A treatment efficacy CAC was performed 15 minutes after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Eyelid Swelling at Duration of Action (16 Hours Post-dose)
A treatment efficacy CAC was performed 16 hours after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Eyelid Swelling at Duration of Action (24 Hours Post-dose)
A treatment efficacy CAC was performed 24 hours after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Eyelid Swelling at Onset of Action (15 Minutes Post-dose)
A treatment efficacy CAC was performed 15 minutes after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Tearing at Duration of Action (16 Hours Post-dose)
A treatment efficacy CAC was performed 16 hours after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Tearing at Duration of Action (24 Hours Post-dose)
A treatment efficacy CAC was performed 24 hours after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Tearing at Onset of Action (15 Minutes Post-dose)
A treatment efficacy CAC was performed 15 minutes after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Rhinorrhea at Duration of Action (16 Hours Post-dose)
A treatment efficacy CAC was performed 16 hours after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Rhinorrhea at Duration of Action (24 Hours Post-dose)
A treatment efficacy CAC was performed 24 hours after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Rhinorrhea at Onset of Action (15 Minutes Post-dose)
A treatment efficacy CAC was performed 15 minutes after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Nasal Pruritus at Duration of Action (16 Hours Post-dose)
A treatment efficacy CAC was performed 16 hours after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Nasal Pruritus at Duration of Action (24 Hours Post-dose)
A treatment efficacy CAC was performed 24 hours after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Nasal Pruritus at Onset of Action (15 Minutes Post-dose)
A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Ear or Palate Pruritus at Duration of Action (16 Hours Post-dose)
A treatment efficacy CAC was performed 16 hours after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Ear or Palate Pruritus at Duration of Action (24 Hours Post-dose)
A treatment efficacy CAC was performed 24 hours after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Ear or Palate Pruritus at Onset of Action (15 Minutes Post-dose)
A treatment efficacy CAC was performed 15 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Nasal Congestion at Onset of Action (16 Hours Post-dose)
A treatment efficacy CAC was performed 16 hours after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Nasal Congestion at Duration of Action (24 Hours Post-dose)
A treatment efficacy CAC was performed 24 hours after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Nasal Congestion at Onset of Action (15 Minutes Post-dose)
A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Nasal Composite Score at Duration of Action (16 Hours Post-dose)
A nasal composite score was summed for each patient based on the presence of at least one of the following four nasal symptoms on a 0-4 scale (0=none to 4=severe): rhinorrhea; nasal pruritus; ear or palate pruritus; and nasal congestion. The percentage of subjects with at least one nasal symptom present was calculated for each time point.
Time frame: 7, 15, 20 minutes post-CAC
Nasal Composite Score at Duration of Action (24 Hours Post-dose)
A nasal composite score was summed for each patient based on the presence of at least one of the following four nasal symptoms on a 0-4 scale (0=none to 4=severe): rhinorrhea; nasal pruritus; ear or palate pruritus; and nasal congestion. The percentage of subjects with at least one nasal symptom present was calculated for each time point.
Time frame: 7, 15, 20 minutes post-CAC
Nasal Composite Score at Onset of Action (15 Minutes Post-dose)
A nasal composite score was summed for each patient based on the presence of at least one of the following four nasal symptoms on a 0-4 scale (0=none to 4=severe): rhinorrhea; nasal pruritus; ear or palate pruritus; and nasal congestion. The percentage of subjects with at least one nasal symptom present was calculated for each time point.
Time frame: 7, 15, 20 minutes post-CAC
Tolerability of Study Medication at Visit 3A
Subjects were asked to rate the comfort of the drop in each eye upon instillation, at 1 minute, and at 2 minutes after instillation of study medication. The assessment used a 10-point scale with 0 as very comfortable and 10 as very uncomfortable. Higher scores represent a worse outcome..
Time frame: upon instillation, 1 minute and 2 minutes post instillation
Subjects were recruited from one site in the US.
| Milestone | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| Started | 25 | 26 | 25 | 25 |
| Completed | 23 | 25 | 21 | 25 |
| Not completed | 2 | 1 | 4 | 0 |
A treatment efficacy CAC was performed 16 hours after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 3 minutes post-CAC | 1.91 ± 0.924 | 2.00 ± 0.771 | 1.65 ± 0.963 | 2.48 ± 0.540 |
| 5 minutes post-CAC | 2.01 ± 1.019 | 2.04 ± 0.889 | 1.74 ± 0.843 | 2.55 ± 0.550 |
| 7 minutes post-CAC | 1.86 ± 0.907 | 1.87 ± 0.913 | 1.75 ± 0.910 | 2.27 ± 0.777 |
A treatment efficacy CAC was performed 24 hours after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 3 minutes post-CAC | 1.99 ± 0.849 | 1.78 ± 0.873 | 1.90 ± 0.804 | 2.24 ± 0.575 |
| 5 minutes post-CAC | 2.00 ± 0.711 | 1.92 ± 0.883 | 2.17 ± 0.819 | 2.24 ± 0.686 |
| 7 minutes post-CAC | 1.77 ± 0.774 | 1.78 ± 0.988 | 1.97 ± 0.833 | 2.08 ± 0.702 |
A treatment efficacy CAC was performed 15 minutes after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 3 minutes post-CAC | 1.05 ± 0.804 | 0.84 ± 0.800 | 0.91 ± 0.810 | 1.94 ± 0.870 |
| 5 minutes post-CAC | 1.19 ± 0.778 | 1.09 ± 0.941 | 1.07 ± 0.840 | 2.09 ± 0.850 |
| 7 minutes post-CAC | 1.01 ± 0.789 | 1.07 ± 0.929 | 0.97 ± 0.843 | 1.94 ± 0.893 |
A treatment efficacy CAC was performed 16 hours after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 1.62 ± 0.634 | 1.59 ± 0.624 | 1.45 ± 0.489 | 1.79 ± 0.359 |
| 15 minutes post-CAC | 1.68 ± 0.606 | 1.65 ± 0.711 | 1.61 ± 0.545 | 1.91 ± 0.426 |
| 20 minutes post-CAC | 1.63 ± 0.696 | 1.58 ± 0.721 | 1.56 ± 0.634 | 1.88 ± 0.403 |
A treatment efficacy CAC was performed 24 hours after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 1.43 ± 0.635 | 1.38 ± 0.668 | 1.71 ± 0.628 | 1.70 ± 0.505 |
| 15 minutes post-CAC | 1.63 ± 0.617 | 1.59 ± 0.663 | 1.85 ± 0.608 | 1.90 ± 0.489 |
| 20 minutes post-CAC | 1.61 ± 0.617 | 1.54 ± 0.677 | 1.79 ± 0.713 | 1.76 ± 0.575 |
A treatment efficacy CAC was performed 15 minutes after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 1.44 ± 0.663 | 1.45 ± 0.812 | 1.66 ± 0.718 | 1.88 ± 0.541 |
| 15 minutes post-CAC | 1.81 ± 0.670 | 1.67 ± 0.821 | 1.83 ± 0.680 | 1.96 ± 0.589 |
| 20 minutes post-CAC | 1.83 ± 0.648 | 1.67 ± 0.868 | 1.79 ± 0.717 | 1.97 ± 0.622 |
A treatment efficacy CAC was performed 16 hours after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 1.47 ± 0.708 | 1.53 ± 0.758 | 1.34 ± 0.684 | 1.81 ± 0.527 |
| 15 minutes post-CAC | 1.60 ± 0.707 | 1.65 ± 0.842 | 1.52 ± 0.732 | 1.99 ± 0.523 |
| 20 minutes post-CAC | 1.60 ± 0.703 | 1.65 ± 0.878 | 1.53 ± 0.788 | 1.95 ± 0.573 |
A treatment efficacy CAC was performed 24 hours after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 1.36 ± 0.730 | 1.22 ± 0.686 | 1.50 ± 0.633 | 1.55 ± 0.582 |
| 15 minutes post-CAC | 1.49 ± 0.596 | 1.47 ± 0.723 | 1.74 ± 0.716 | 1.77 ± 0.544 |
| 20 minutes post-CAC | 1.50 ± 0.617 | 1.47 ± 0.701 | 1.65 ± 0.736 | 1.65 ± 0.599 |
A treatment efficacy CAC was performed 15 minutes after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 1.24 ± 0.689 | 1.24 ± 0.867 | 1.27 ± 0.858 | 1.67 ± 0.628 |
| 15 minutes post-CAC | 1.59 ± 0.749 | 1.51 ± 0.861 | 1.64 ± 0.669 | 1.77 ± 0.661 |
| 20 minutes post-CAC | 1.65 ± 0.647 | 1.52 ± 0.952 | 1.73 ± 0.622 | 1.79 ± 0.644 |
A treatment efficacy CAC was performed 16 hours after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 1.68 ± 0.602 | 1.74 ± 0.690 | 1.57 ± 0.497 | 1.90 ± 0.439 |
| 15 minutes post-CAC | 1.81 ± 0.639 | 1.77 ± 0.757 | 1.69 ± 0.605 | 2.02 ± 0.484 |
| 20 minutes post-CAC | 1.80 ± 0.629 | 1.73 ± 0.797 | 1.69 ± 0.647 | 1.97 ± 0.458 |
A treatment efficacy CAC was performed 24 hours after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 1.53 ± 0.590 | 1.37 ± 0.681 | 1.73 ± 0.616 | 1.80 ± 0.505 |
| 15 minutes post-CAC | 1.72 ± 0.585 | 1.63 ± 0.700 | 1.90 ± 0.657 | 2.00 ± 0.505 |
| 20 minutes post-CAC | 1.70 ± 0.579 | 1.60 ± 0.688 | 1.87 ± 0.696 | 1.85 ± 0.530 |
A treatment efficacy CAC was performed 15 minutes after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 1.52 ± 0.644 | 1.49 ± 0.782 | 1.64 ± 0.744 | 1.93 ± 0.508 |
| 15 minutes post-CAC | 1.86 ± 0.652 | 1.73 ± 0.803 | 1.98 ± 0.698 | 2.01 ± 0.575 |
| 20 minutes post-CAC | 1.91 ± 0.577 | 1.72 ± 0.861 | 1.88 ± 0.644 | 2.04 ± 0.598 |
A treatment efficacy CAC was performed 16 hours after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 0.71 ± 0.553 | 0.58 ± 0.406 | 0.53 ± 0.292 | 0.72 ± 0.532 |
| 15 minutes post-CAC | 0.93 ± 0.557 | 0.70 ± 0.545 | 0.60 ± 0.354 | 0.99 ± 0.575 |
| 20 minutes post-CAC | 0.92 ± 0.644 | 0.72 ± 0.583 | 0.71 ± 0.460 | 1.00 ± 0.650 |
A treatment efficacy CAC was performed 24 hours after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 0.68 ± 0.478 | 0.52 ± 0.279 | 0.55 ± 0.298 | 0.68 ± 0.399 |
| 15 minutes post-CAC | 0.87 ± 0.612 | 0.64 ± 0.396 | 0.77 ± 0.433 | 0.81 ± 0.532 |
| 20 minutes post-CAC | 0.90 ± 0.647 | 0.71 ± 0.419 | 0.84 ± 0.572 | 0.90 ± 0.568 |
A treatment efficacy CAC was performed 15 minutes after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 0.49 ± 0.232 | 0.43 ± 0.293 | 0.54 ± 0.277 | 0.74 ± 0.427 |
| 15 minutes post-CAC | 0.74 ± 0.423 | 0.52 ± 0.314 | 0.79 ± 0.456 | 0.80 ± 0.554 |
| 20 minutes post-CAC | 0.71 ± 0.403 | 0.53 ± 0.363 | 0.76 ± 0.399 | 0.88 ± 0.555 |
A treatment efficacy CAC was performed 16 hours after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 0.6 ± 0.75 | 0.8 ± 0.66 | 0.8 ± 0.66 | 0.9 ± 0.71 |
| 15 minutes post-CAC | 0.7 ± 0.79 | 0.9 ± 0.75 | 0.8 ± 0.54 | 1.1 ± 0.86 |
| 20 minutes post-CAC | 0.6 ± 0.76 | 0.8 ± 0.73 | 0.7 ± 0.56 | 1.0 ± 0.85 |
A treatment efficacy CAC was performed 24 hours after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 0.7 ± 0.60 | 0.7 ± 0.54 | 0.9 ± 0.68 | 0.7 ± 0.74 |
| 15 minutes post-CAC | 0.8 ± 0.70 | 0.8 ± 0.73 | 0.9 ± 0.82 | 0.9 ± 0.82 |
| 20 minutes post-CAC | 0.8 ± 0.69 | 0.8 ± 0.76 | 0.9 ± 0.72 | 0.9 ± 0.85 |
A treatment efficacy CAC was performed 15 minutes after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 0.4 ± 0.56 | 0.5 ± 0.70 | 0.5 ± 0.49 | 0.7 ± 0.81 |
| 15 minutes post-CAC | 0.5 ± 0.68 | 0.6 ± 0.65 | 0.6 ± 0.65 | 0.8 ± 0.89 |
| 20 minutes post-CAC | 0.5 ± 0.71 | 0.6 ± 0.58 | 0.5 ± 0.49 | 0.7 ± 0.84 |
A treatment efficacy CAC was performed 16 hours after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 1.0 ± 1.07 | 0.8 ± 0.72 | 0.6 ± 0.51 | 0.6 ± 0.67 |
| 15 minutes post-CAC | 0.8 ± 0.89 | 0.5 ± 0.64 | 0.7 ± 0.65 | 0.9 ± 0.82 |
| 20 minutes post-CAC | 0.7 ± 0.85 | 0.4 ± 0.63 | 0.7 ± 0.62 | 0.9 ± 0.97 |
A treatment efficacy CAC was performed 24 hours after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 1.0 ± 0.78 | 0.7 ± 0.61 | 0.6 ± 0.75 | 0.8 ± 0.71 |
| 15 minutes post-CAC | 1.1 ± 0.79 | 0.6 ± 0.54 | 0.7 ± 0.66 | 0.8 ± 0.82 |
| 20 minutes post-CAC | 1.0 ± 0.77 | 0.5 ± 0.53 | 0.7 ± 0.72 | 0.7 ± 0.84 |
A treatment efficacy CAC was performed 15 minutes after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 0.7 ± 0.74 | 0.5 ± 0.49 | 0.3 ± 0.56 | 0.6 ± 0.64 |
| 15 minutes post-CAC | 0.5 ± 0.66 | 0.5 ± 0.50 | 0.4 ± 0.50 | 0.6 ± 0.64 |
| 20 minutes post-CAC | 0.5 ± 0.60 | 0.4 ± 0.47 | 0.2 ± 0.33 | 0.6 ± 0.90 |
A treatment efficacy CAC was performed 16 hours after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 1.1 ± 1.26 | 0.4 ± 0.49 | 0.7 ± 0.99 | 0.7 ± 0.80 |
| 15 minutes post-CAC | 1.2 ± 1.01 | 0.6 ± 0.77 | 1.1 ± 1.04 | 1.0 ± 1.12 |
| 20 minutes post-CAC | 1.3 ± 1.14 | 0.7 ± 0.80 | 1.1 ± 1.05 | 1.1 ± 1.24 |
A treatment efficacy CAC was performed 24 hours after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 1.1 ± 1.28 | 0.6 ± 0.65 | 0.8 ± 0.90 | 0.7 ± 0.69 |
| 15 minutes post-CAC | 1.1 ± 1.29 | 0.7 ± 0.69 | 1.2 ± 0.91 | 1.0 ± 0.84 |
| 20 minutes post-CAC | 1.2 ± 1.28 | 0.6 ± 0.70 | 1.0 ± 0.71 | 0.8 ± 0.90 |
A treatment efficacy CAC was performed 15 minutes after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 0.6 ± 1.20 | 0.2 ± 0.41 | 0.3 ± 0.58 | 0.6 ± 0.82 |
| 15 minutes post-CAC | 0.9 ± 1.25 | 0.4 ± 0.65 | 0.5 ± 0.75 | 0.8 ± 0.87 |
| 20 minutes post-CAC | 0.8 ± 1.23 | 0.4 ± 0.71 | 0.5 ± 0.68 | 0.6 ± 0.70 |
A treatment efficacy CAC was performed 16 hours after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 0.6 ± 0.91 | 0.2 ± 0.37 | 0.5 ± 0.65 | 0.4 ± 0.71 |
| 15 minutes post-CAC | 0.6 ± 0.91 | 0.4 ± 0.65 | 0.7 ± 0.80 | 0.8 ± 1.01 |
| 20 minutes post-CAC | 0.7 ± 0.99 | 0.6 ± 0.91 | 0.6 ± 0.65 | 0.8 ± 1.13 |
A treatment efficacy CAC was performed 24 hours after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 0.7 ± 0.93 | 0.4 ± 0.64 | 0.4 ± 0.58 | 0.4 ± 0.82 |
| 15 minutes post-CAC | 0.7 ± 1.03 | 0.4 ± 0.58 | 0.8 ± 0.93 | 0.6 ± 0.99 |
| 20 minutes post-CAC | 0.5 ± 0.90 | 0.5 ± 0.65 | 0.6 ± 0.82 | 0.7 ± 0.85 |
A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 0.4 ± 0.99 | 0.2 ± 0.37 | 0.3 ± 0.56 | 0.4 ± 0.65 |
| 15 minutes post-CAC | 0.4 ± 0.84 | 0.3 ± 0.56 | 0.2 ± 0.44 | 0.4 ± 0.58 |
| 20 minutes post-CAC | 0.4 ± 0.95 | 0.4 ± 0.64 | 0.3 ± 0.66 | 0.4 ± 0.65 |
A treatment efficacy CAC was performed 16 hours after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 0.4 ± 0.87 | 0.4 ± 0.57 | 0.3 ± 0.74 | 0.5 ± 0.87 |
| 15 minutes post-CAC | 0.9 ± 1.09 | 0.8 ± 0.90 | 0.5 ± 0.77 | 1.0 ± 1.10 |
| 20 minutes post-CAC | 0.8 ± 1.11 | 0.9 ± 0.91 | 0.8 ± 0.93 | 1.2 ± 1.31 |
A treatment efficacy CAC was performed 24 hours after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 0.6 ± 0.89 | 0.3 ± 0.46 | 0.4 ± 0.76 | 0.5 ± 0.96 |
| 15 minutes post-CAC | 0.7 ± 0.96 | 0.6 ± 0.65 | 0.7 ± 0.98 | 0.8 ± 1.19 |
| 20 minutes post-CAC | 0.8 ± 1.11 | 0.7 ± 0.74 | 0.7 ± 0.90 | 0.7 ± 1.07 |
A treatment efficacy CAC was performed 15 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 0.6 ± 0.99 | 0.2 ± 0.52 | 0.3 ± 0.56 | 0.4 ± 0.76 |
| 15 minutes post-CAC | 08 ± 0.95 | 0.4 ± 0.76 | 0.3 ± 0.58 | 0.7 ± 1.07 |
| 20 minutes post-CAC | 0.7 ± 1.01 | 0.5 ± 0.77 | 0.3 ± 0.58 | 0.7 ± 1.07 |
A treatment efficacy CAC was performed 16 hours after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 1.2 ± 0.99 | 0.5 ± 0.65 | 0.8 ± 1.18 | 0.8 ± 0.78 |
| 15 minutes post-CAC | 1.4 ± 1.04 | 0.6 ± 0.76 | 1.0 ± 1.19 | 1.2 ± 0.85 |
| 20 minutes post-CAC | 1.5 ± 1.05 | 0.8 ± 0.99 | 1.0 ± 1.14 | 1.3 ± 1.21 |
A treatment efficacy CAC was performed 24 hours after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 0.9 ± 0.97 | 0.6 ± 0.58 | 0.8 ± 0.80 | 0.7 ± 0.69 |
| 15 minutes post-CAC | 1.2 ± 0.98 | 0.6 ± 0.58 | 1.2 ± 0.94 | 1.1 ± 0.83 |
| 20 minutes post-CAC | 1.2 ± 1.00 | 0.6 ± 0.65 | 1.1 ± 1.04 | 1.2 ± 0.88 |
A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 0.7 ± 1.05 | 0.4 ± 0.58 | 0.4 ± 0.59 | 0.8 ± 0.78 |
| 15 minutes post-CAC | 1.1 ± 1.08 | 0.5 ± 0.65 | 0.4 ± 0.59 | 1.4 ± 0.86 |
| 20 minutes post-CAC | 1.1 ± 1.14 | 0.5 ± 0.65 | 0.4 ± 0.59 | 1.4 ± 0.87 |
A nasal composite score was summed for each patient based on the presence of at least one of the following four nasal symptoms on a 0-4 scale (0=none to 4=severe): rhinorrhea; nasal pruritus; ear or palate pruritus; and nasal congestion. The percentage of subjects with at least one nasal symptom present was calculated for each time point.
| percentage of subjects | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 82.6 | 66.7 | 52.4 | 76.0 |
| 15 minutes post-CAC | 82.6 | 79.2 | 90.5 | 84.0 |
| 20 minutes post-CAC | 91.3 | 83.3 | 95.2 | 84.0 |
A nasal composite score was summed for each patient based on the presence of at least one of the following four nasal symptoms on a 0-4 scale (0=none to 4=severe): rhinorrhea; nasal pruritus; ear or palate pruritus; and nasal congestion. The percentage of subjects with at least one nasal symptom present was calculated for each time point.
| percentage of subjects | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 69.6 | 76.0 | 85.7 | 68.0 |
| 15 minutes post-CAC | 82.6 | 84.0 | 90.5 | 92.0 |
| 20 minutes post-CAC | 82.6 | 88.0 | 81.0 | 92.0 |
A nasal composite score was summed for each patient based on the presence of at least one of the following four nasal symptoms on a 0-4 scale (0=none to 4=severe): rhinorrhea; nasal pruritus; ear or palate pruritus; and nasal congestion. The percentage of subjects with at least one nasal symptom present was calculated for each time point.
| percentage of subjects | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| 7 minutes post-CAC | 52.2 | 56 | 47.6 | 72 |
| 15 minutes post-CAC | 82.6 | 56 | 47.6 | 84 |
| 20 minutes post-CAC | 73.9 | 52 | 52.4 | 84 |
Subjects were asked to rate the comfort of the drop in each eye upon instillation, at 1 minute, and at 2 minutes after instillation of study medication. The assessment used a 10-point scale with 0 as very comfortable and 10 as very uncomfortable. Higher scores represent a worse outcome..
| units on a scale | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| Upon instillation | 0.5 ± 0.95 | 0.7 ± 1.04 | 1.3 ± 1.93 | 0.6 ± 1.03 |
| 1 minute post-instillation | 0.7 ± 1.13 | 0.9 ± 1.13 | 2.0 ± 2.25 | 0.9 ± 1.18 |
| 2 minutes post-instillation | 0.8 ± 1.10 | 1.0 ± 1.18 | 1.7 ± 2.27 | 0.6 ± 0.79 |
Collected over Adverse events were assessed through study completion, approximately two months. All subjects who received study medication were evaluable for the safety analysis.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AC-170 0.05% | — | 0/25 (0%) | 6/25 (24%) |
| AC-170 0.1% | — | 0/26 (0%) | 3/26 (11.5%) |
| AC-170 0.24% | — | 0/25 (0%) | 4/25 (16%) |
| AC-170 0% | — | 0/25 (0%) | 2/25 (8%) |
| Event | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% |
|---|---|---|---|---|
| Visual acuity reducsedEye disorders | 2/25 | 1/26 | 0/25 | 1/25 |
| PhotophobiaEye disorders | 0/25 | 0/26 | 1/25 | 0/25 |
| PetechiaeSkin and subcutaneous tissue disorders | 0/25 | 0/26 | 0/25 | 1/25 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 0/25 | 0/26 | 1/25 | 0/25 |
| Back painMusculoskeletal and connective tissue disorders | 1/25 | 0/26 | 0/25 | 0/25 |
| Oral pruritusGastrointestinal disorders | 1/25 | 0/26 | 0/25 | 0/25 |
| Palatal OedemaGastrointestinal disorders | 1/25 | 0/26 | 0/25 | 0/25 |
| NasopharyngitisInfections and infestations | 1/25 | 0/26 | 0/25 | 0/25 |
| HeadacheNervous system disorders | 0/25 | 0/26 | 1/25 | 0/25 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/25 | 0/26 | 1/25 | 0/25 |
| Age, Continuous(years) | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% | Total |
|---|---|---|---|---|---|
| Mean | 45.5 ± 13.58 | 43.1 ± 13.5 | 38.9 ± 12.53 | 38.1 ± 14.12 | 41.4 ± 13.59 |
| Sex: Female, Male(Participants) | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% | Total |
|---|---|---|---|---|---|
| Female | 17 | 15 | 10 | 14 | 56 |
| Male | 8 | 11 | 15 | 11 | 45 |
| Ethnicity (NIH/OMB)(Participants) | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 5 | 3 | 5 | 16 |
| Not Hispanic or Latino | 22 | 21 | 22 | 20 | 85 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 1 | 1 | 4 |
| White | 24 | 25 | 24 | 23 | 96 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | AC-170 0.05% | AC-170 0.1% | AC-170 0.24% | AC-170 0% | Total |
|---|---|---|---|---|---|
| United States | 25 | 26 | 25 | 25 | 101 |
The record gives a start of Apr 2011, a primary completion of Jun 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2017, 6 years 2 months after primary completion. A results delay was requested in Jul 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cetirizine
Aciex Therapeutics, Inc.